KaydedilenlerDerginizi ekleyin

Dergiler / Haydarpaşa Numune Medical Journal / 2021 / Cilt: 61 - Sayı: 2

Comparison of Rifaximin and Trimebutin Maleate Treatment for Irritable Bowel Syndrome with Constipation and Diarrhea

Bilge Örmeci BAŞ
Sayfa
197–203
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Discussion and Conclusion: The use of rifaximin provides significant long-term improvement in both diarrhea and consti- pation IBS patients compared to Trimebutin Maleate treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with changes in bowel habits, abdomi- nal pain, and gas without any organic pathology.
📊
Temel Bulgular & Veri:Rifaximin at a dose of 200 mg, 3×2 daily for 15 days.
💡
Sonuç & Katkı:Discussion and Conclusion: The use of rifaximin provides significant long-term improvement in both diarrhea and consti- pation IBS patients compared to Trimebutin Maleate treatment.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with changes in bowel habits, abdomi- nal pain, and gas without any organic pathology. IBS is divided into three types as constipation – IBS (IBS-C), diarrhea – IBS (IBS-D), and mixed. Rifaximin is an antibiotic that improves IBS symptoms by improving the flora in the intestine. The aim of the study was to determine whether the treatment of rifaximin is superior to treatment. Methods: This study performed retrospectively and patients were divided into two groups as IBS-C and IBS-D. Each group was divided into two groups as rifaximin and Trimebutin Maleate treatment. Rifaximin at a dose of 200 mg, 3×2 daily for 15 days. Trimebutin Maleate group includes lifestyle modification and Trimebutin Maleate 200 mg 3×1. At the end of the treat- ment and after 20 days, the patients were re-evaluated. Results: A total of 179 subjects had examined. In terms of IBS symptoms; bloating, abdominal pain, and stool consistency, both treatments are effective as long as patients continue treatment; however, 20 days after the end of the treatment, rifax- imin treatment was found to be more effective than trimebutin maleate treatment. Discussion and Conclusion: The use of rifaximin provides significant long-term improvement in both diarrhea and consti- pation IBS patients compared to Trimebutin Maleate treatment.

🔖

Bu Makaleye Atıf Yap

BAŞ, B. Ö. (2022). Comparison of Rifaximin and Trimebutin Maleate Treatment for Irritable Bowel Syndrome with Constipation and Diarrhea. Haydarpaşa Numune Medical Journal, Cilt: 61 - Sayı: 2, 197–203. https://ajindex.com/articles/535914

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Brandt LJ, Chey WD, Foxx-Orenstein AE. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:1–35
  2. Dupont HL. Review article: Evidence for the role of gut mi- crobiota in irritable bowel syndrome and its potential in- fluence on therapeutic targets. Aliment Pharmacol Ther 2014;39:1033–42
  3. Lacy BE, Chey WD, Lembo AJ. New and emerging treatment options for ırritable bowel syndrome. Gastroenterol Hepatol (N Y) 2015;11:1–19
  4. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic 225 (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann In- tern Med 2006;145:557–63
  5. Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intes- tine bacterial overgrowth and irritable bowel syndrome-relat- ed symptoms: Experience with rifaximin. World J Gastroenter- ol 2009;15:2628–31
  6. Lembo A, Zakko SF, Ferreira NL, Ringel Y, Bortey E, Courtney K, et al. Rifaximin for the treatment of diarrhea-associated irri- table bowel syndrome: Short term treatment leading to long term sustained response. Gastroenterology 2008;134:545
  7. Ghoshal, UC, Srivastava D, Misra A. A randomized dou- ble-blind placebo-controlled trial showing rifaximin to im- prove constipation by reducing methane production and accelerating colon transit: A pilot 235 study. Indian J Gastro- enterol 2018;37:416–23
  8. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22–32
  9. Pimentel M, Morales W, Chua K, Barlow G, Weitsman S, Kim G, et al. Effects of rifaximin treatment and retreatment in non constipated IBS subjects. Dig Dis Sci 2011;56:2067–72
  10. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin ıs safe and effective in patients with diarrhea predominant ırritable bowel syn- drome. Gastroenterology 2016;151:1113–21
  11. Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, et al. Antibiotic treatment of constipation predominant irritable bowel syndrome. Dig Dis Sci 2014;59:1278–85.